bioMerieux (0RUG) Stock Statistics & Valuation Metrics
Total Valuation
bioMerieux has a market cap or net worth of EUR 10.69B. The enterprise value is EUR 7.90B.
- Market Cap
- EUR 10.69B
- Enterprise Value
- EUR 7.90B
Share Statistics
bioMerieux has 118,361,220 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 118,361,220
- Owned by Insiders
- ―
- Owned by Institutions
- 8.15%
Financial Efficiency
bioMerieux’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 9.13%.
- Return on Equity (ROE)
- 0.10
- Return on Assets (ROA)
- 0.07
- Return on Invested Capital (ROIC)
- 9.13%
- Return on Capital Employed (ROCE)
- 0.12
- Revenue Per Employee
- 273.25K
- Profits Per Employee
- 26.69K
- Employee Count
- 14,894
- Asset Turnover
- 0.73
- Inventory Turnover
- 1.98
Valuation Ratios
The current PE Ratio of bioMerieux is 23.03. bioMerieux’s PEG ratio is 0.99.
- PE Ratio
- 23.03
- PS Ratio
- 2.67
- PB Ratio
- 2.48
- Price to FCF
- 18.19
- Price to Operating Cash Flow
- 11.74
- PEG Ratio
- 0.99
Income Statement
In the last 12 months, bioMerieux had revenue of 4.07B and earned 397.50M in profits. Earnings per share was 3.37.
- Revenue
- 4.07B
- Gross Profit
- 2.14B
- Operating Income
- 561.20M
- Pretax Income
- 525.50M
- Net Income
- 397.50M
- EBITDA
- 999.60M
- Earnings Per Share (EPS)
- 3.37
Cash Flow
In the last 12 months, operating cash flow was 907.60M and capital expenditures -322.10M, giving a free cash flow of 585.50M billion.
- Operating Cash Flow
- 907.60M
- Free Cash Flow
- 585.50M
- Free Cash Flow per Share
- 4.97
Dividends & Yields
bioMerieux pays an annual dividend of ―, resulting in a dividend yield of 1.08%
- Dividend Per Share
- ―
- Dividend Yield
- 1.08%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 5.50%
- Earnings Yield
- 4.34%
Stock Price Statistics
- Beta
- 0.96
- 52-Week Price Change
- -18.35%
- 50-Day Moving Average
- 79.19
- 200-Day Moving Average
- 79.90
- Relative Strength Index (RSI)
- 73.39
- Average Volume (3m)
- 72.69K
Important Dates
bioMerieux upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Jul 28, 2026
- Next Earnings Date
- Mar 04, 2027
- Ex-Dividend Date
- ―
Financial Position
bioMerieux as a current ratio of 2.39, with Debt / Equity ratio of 11.25%
- Current Ratio
- 2.39
- Quick Ratio
- 1.47
- Debt to Market Cap
- 0.02
- Net Debt to EBITDA
- -0.11
- Interest Coverage Ratio
- 35.52
Taxes
In the past 12 months, bioMerieux has paid 128.80M in taxes.
- Income Tax
- 128.80M
- Effective Tax Rate
- 0.25
Enterprise Valuation
bioMerieux EV to EBITDA ratio is 11.36, with an EV/FCF ratio of 17.79.
- EV to Sales
- 2.61
- EV to EBITDA
- 11.36
- EV to Free Cash Flow
- 17.79
- EV to Operating Cash Flow
- 11.48
Balance Sheet
bioMerieux has EUR 657.70M in cash and marketable securities with EUR 421.80M in debt, giving a net cash position of EUR 235.90M billion.
- Cash & Marketable Securities
- EUR 657.70M
- Total Debt
- EUR 421.80M
- Net Cash
- EUR 235.90M
- Net Cash Per Share
- EUR 1.99
- Tangible Book Value Per Share
- EUR 26.55
Margins
Gross margin is 52.04%, with operating margin of 11.99%, and net profit margin of 11.59%.
- Gross Margin
- 52.04%
- Operating Margin
- 11.99%
- Pretax Margin
- 15.21%
- Net Profit Margin
- 11.59%
- EBITDA Margin
- 22.98%
- EBIT Margin
- 11.99%
Analyst Forecast
The average price target for bioMerieux is EUR 83.50, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- EUR 83.50
- Price Target Upside
- 7.99% Downside
- Analyst Consensus
- Neutral
- Analyst Count
- 4
- Revenue Growth Forecast
- -3.18%
- EPS Growth Forecast
- 22.52%
